Appendix 4E and 2026 Annual Report
Filed with ASX · · 69 pages · English
Summary by 6ix AI
The report highlights a slight decline in revenue but a significant reduction in net loss compared to the previous year, reflecting improved expenditure discipline. The company has not declared any dividends during the reporting period and remains focused on advancing its innovative drug candidates.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Argent Biopharma
- FDA-CVM Establish INAD File for CannEpil Veterinary Program
- US Veterinary Development Programme for CannEpil Commences
- CannEpil Global Licence Expands into Veterinary Healthcare
- RGT Executes Global CannEpil Licensing Deal for US$5.5M
- Half Yearly Report and Accounts
Later from Argent Biopharma
- Argent Signs NLC Licence to Expand Antiviral Portfolio
- Execution of Loan Facility Agreement
- Quarterly Activities/Appendix 4C Cash Flow Report
- RGT Executes Global Licence for Non-Core Cannabis Genetics
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma